AstraZeneca and Incyte are collaborating on a trial evaluating a new combination drug to treat lung cancer.

The firms will collaborate on a Phase I / II trial, which will be conducted by Incyte.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial is designed to evaluate the efficacy and safety of Incyte’s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in combination with AstraZeneca’s next-generation epidermal growth factor receptor (EGFR) inhibitor, Tagrisso (osimertinib).

The combination will be evaluated as a second line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who have been treated with a first generation EGFR tyrosine kinase inhibitor (TKI) and subsequently developed the T790M resistance mutation.

"This collaboration allows us to explore further ways in which Tagrisso, our first in class T790M-directed tyrosine kinase inhibitor, can help meet urgent unmet patient need."

The trial’s Phase I is expected to establish a recommended dose regimen for the combination, while Phase II will evaluate its safety and efficacy.

See Also:

Results from the trial will be used to determine whether further clinical development of the combination is warranted.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AstraZeneca Oncology, Global Medicines Development head Antoine Yver said: "We are pleased to be building on our existing relationship with Incyte and exploring a potentially exciting combination for lung cancer patients who have developed a resistance to first generation EGFR inhibitor treatment.

"This collaboration allows us to explore further ways in which Tagrisso, our first in class T790M-directed tyrosine kinase inhibitor, can help meet urgent unmet patient need, following its accelerated approval in the US and the recent positive CHMP opinion, recommending approval in Europe."

There is increasing evidence that signalling through the JAK-STAT pathway could be a contributing factor in resistance to EGFR TKI treatment in patients with EGFR mutation NSCLC.

Blocking both JAK and EGFR activity may offer an improved, targeted treatment benefit in some patients.

The new agreement builds on an existing collaboration between the two companies signed in May 2014, which explored AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor, durvalumab, in combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, epacadostat (INCB24360).

AstraZeneca’s Tagrisso is the only approved medicine indicated for adult patients with metastatic EGFR T790M mutation-positive NSCLC.

This indication is approved under the US Food and Drug Administration (FDA’s) accelerated approval process based on tumour response rate and duration of response (DoR).

Osimertinib is currently being compared with platinum-based doublet chemotherapy in the confirmatory AURA3 Phase III trial in patients with EGFR T790M-positive, locally advanced, or metastatic NSCLC who have progressed after EGFR-TKI therapy.